Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Blood Pressure Medication Recalls

Recalls of ARBs, ACE inhibitors, beta blockers and other hypertension drugs - the class behind the large valsartan and losartan nitrosamine recalls.

549 recalls in this category, newest first.

Class II · Moderate risk

Benazepril HCl active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-537-2015
Class II · Moderate risk

Benazepril active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-536-2015
Class II · Moderate risk

Amlodipine besylate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-518-2015
Class II · Moderate risk

Amlodipine active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-517-2015
Class III · Low risk

Candesartan Cilexetil Tablets

Failed Impurities/Degradation Specifications: Out of specification (OOS) results were observed for CAD-II, CAD-V and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-3621-3 D-0244-2015
Class III · Low risk

Candesartan Cilexetil Tablets

Failed Impurities/Degradation Specifications: Out of specification (OOS) results were observed for CAD-II, CAD-V and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-3620-3 D-0243-2015
Class III · Low risk

Candesartan Cilexetil Tablets

Failed Impurities/Degradation Specifications: Out of specification (OOS) results were observed for CAD-II, CAD-V and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-3619-3 D-0242-2015
Class III · Low risk

Candesartan Cilexetil Tablets

Failed Impurities/Degradation Specifications: Out of specification (OOS) results were observed for CAD-II, CAD-V and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-3618-3 D-0241-2015
Class III · Low risk

candesartan cilexetil

Failed Impurities/Degradation Specifications: An Out of Specification (OOS) result was generated for the 18 month stability time point for ketone cilexetil impurity and total impurities.

Terminated Impurity / degradation Sandoz, Inc NDC 0781-5938-92 D-0288-2015
Class III · Low risk

Amlodipine Besylate Tablets

Discoloration: Brown spots were noted embedded in Amlodipine Besylate Tablets, 10 mg, Lot # MP4344.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-123-16 D-0257-2015
Class II · Moderate risk

ZyGenerics ATENOLOL Tablets

Superpotent Drug: A complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance.

Terminated Wrong potency / content Zydus Pharmaceuticals USA Inc NDC 68382-022-01 D-0007-2015
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-107-30 D-1508-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-106-30 D-1507-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-104-30 D-1506-2014
Class II · Moderate risk

Tribenzor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-116-30 D-1504-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-105-30 D-1503-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-103-30 D-1502-2014
Class II · Moderate risk

Azor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-113-30 D-1501-2014
Class III · Low risk

Vasotec (enalapril maleate)

Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.

Terminated Labeling / mix-up Valeant Pharmaceuticals North America LLC NDC 0187-0140-90 D-0019-2015